Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Urinalysis is attractive in non-invasive early diagnosis of bladder cancer compared with clinical gold standard cystoscopy. However, the trace bladder tumor biomarkers in urine and the particularly complex urine environment pose significant challenges for urinalysis. Here, a clinically adoptable urinalysis device that integrates molecular-specificity indium gallium zinc oxide field-effect transistor (IGZO FET) biosensor arrays, a device control panel, and an internet terminal for directly analyzing five bladder-tumor-associated proteins in clinical urine samples, is reported for bladder cancer diagnosis and classification. The IGZO FET biosensors with engineered sensing interfaces provide high sensitivity and selectivity for identification of trace proteins in the complex urine environment. Integrating with a machine-learning algorithm, this device can identify bladder cancer with an accuracy of 95.0% in a cohort of 197 patients and 75 non-bladder cancer individuals, distinguishing cancer stages with an overall accuracy of 90.0% and assessing bladder cancer recurrence after surgical treatment. The non-invasive urinalysis device defines a robust technology for remote healthcare and personalized medicine. © 2022 Wiley-VCH GmbH.

Citation

Yanbing Yang, Jingfeng Wang, Wanting Huang, Guojia Wan, Miaomiao Xia, Duo Chen, Yun Zhang, Yiming Wang, Fuding Guo, Jie Tan, Huageng Liang, Bo Du, Lilei Yu, Weihong Tan, Xiangfeng Duan, Quan Yuan. Integrated Urinalysis Devices Based on Interface-Engineered Field-Effect Transistor Biosensors Incorporated With Electronic Circuits. Advanced materials (Deerfield Beach, Fla.). 2022 Sep;34(36):e2203224

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 35853614

View Full Text